☆ 4.6 Article

Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates

CANCER IMAGING (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Gastroenterology & Hepatology

Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma

Isabelle Ollivier-Hourmand et al.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Baveno VII - Renewing consensus in portal hypertension

Roberto de Franchis et al.

Summary: The Baveno VII workshop focused on personalized care for portal hypertension in patients with compensated cirrhosis or cACLD, discussing various aspects including diagnosis, treatment, and prevention measures in 9 main topics, resulting in a series of consensus recommendations.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Lukas Mueller et al.

Summary: In a cohort of Western patients with HCC undergoing TACE treatment, more than two thirds had CEPH. Patients with CEPH had significantly impaired survival in univariate analysis, but did not reach significance in multivariate analysis.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Emerging immunotherapy or HCC: A guide for hepatologists

Friedrich Foerster et al.

Summary: HCC is one of the most common and deadliest cancers globally. Immuno-oncology has shown promising results in the treatment of HCC, with immune checkpoint inhibition becoming the first-line therapy for advanced cases. However, challenges remain in determining the role of immunotherapy in earlier stages of HCC and identifying treatment strategies for non-responsive patients.

HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi et al.

Summary: This study confirms the reproducible safety and efficacy of atezolizumab plus bevacizumab in routine clinical practice for patients with unresectable hepatocellular carcinoma. The presence of portal vein tumor thrombosis (PVTT) and higher ALBI grade are indicators of poorer survival in patients who meet the Child-Pugh-A criteria.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Global burden of primary liver cancer in 2020 and predictions to 2040

Harriet Rumgay et al.

Summary: The burden of liver cancer varies across the world, and it is a major cause of death in many countries. The number of liver cancer cases and deaths is predicted to increase, with a significant rise expected by 2040.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC

Lukas Mueller et al.

Summary: This study trained a deep-learning algorithm to assess spleen volume (SV) in patients with hepatocellular carcinoma (HCC) and investigated SV as a prognostic factor for patients undergoing transarterial chemoembolization (TACE). The results showed that automated SV assessments were superior to two-dimensional spleen size estimates in predicting survival and identifying patients at risk of hepatic decompensation.

EUROPEAN RADIOLOGY (2022)

添加到收藏夹

Letter Gastroenterology & Hepatology

Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma

Isabelle Ollivier-Hourmand et al.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

The Current Landscape of Clinical Trials for Systemic Treatment of HCC

Friedrich Foerster et al.

Summary: Liver cancer is a life-threatening disease where drugs play a vital role in treatment, and immunotherapy has emerged as a significant innovation. Clinical trials are investigating the benefits of immunotherapy and other treatment approaches for liver cancer.

CANCERS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses horizontal ellipsis

Manon Allaire et al.

Summary: The review highlights the complications of portal hypertension and hepatocellular carcinoma in cirrhosis patients, emphasizing the challenges in treatment when both conditions coexist. Studies suggest that the combination of Atezolizumab and Bevacizumab may impact portal hypertension levels and related complications, but real-life data are lacking to support this. Management of portal hypertension remains crucial to improve outcomes for patients with hepatocellular carcinoma.

LIVER INTERNATIONAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Computer Science, Artificial Intelligence

Fully Automatic Volume Measurement of the Spleen at CT Using Deep Learning

Gabriel E. Humpire-Mamani et al.

RADIOLOGY-ARTIFICIAL INTELLIGENCE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension

Xiaolong Qi et al.

RADIOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study

Yanna Liu et al.

LANCET (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma

Jin Woo Choi et al.

EUROPEAN RADIOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization

Nam Hee Kim et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

The Best Single Measurement for Assessing Splenomegaly in Patients with Cirrhotic Liver Morphology

Zachary Nuffer et al.

ACADEMIC RADIOLOGY (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Non-invasive prediction of portal pressures using CT and MRI in chronic liver disease

Shingo Kihira et al.

ABDOMINAL RADIOLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Portal Hypertension and the Outcome of Surgery for Hepatocellular Carcinoma in Compensated Cirrhosis: A Systematic Review and Meta-analysis

Annalisa Berzigotti et al.

HEPATOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma

Pouya Iranmanesh et al.

JOURNAL OF HEPATOLOGY (2014)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Assessing Splenomegaly: Automated Volumetric Analysis of the Spleen

Marius George Linguraru et al.

ACADEMIC RADIOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study

M. Pinter et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)

添加到收藏夹

Letter Gastroenterology & Hepatology

Letter: sorafenib in portal hypertension

B. Procopet et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study

Hisashi Hidaka et al.

JOURNAL OF GASTROENTEROLOGY (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials

Ping Fang et al.

PLOS ONE (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib

Romain Coriat et al.

PLOS ONE (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats

Marc Mejias et al.

HEPATOLOGY (2009)

添加到收藏夹

Article Gastroenterology & Hepatology

Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats

Thomas Reiberger et al.

JOURNAL OF HEPATOLOGY (2009)

添加到收藏夹

Review Gastroenterology & Hepatology

The clinical use of HVPG measurements in chronic liver disease

Jaime Bosch et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)

添加到收藏夹

Article Gastroenterology & Hepatology

Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma

Takeaki Ishizawa et al.

GASTROENTEROLOGY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.